Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Surgical delay after biopsy and risk of upstaging for clinical T1a renal cell carcinoma

Improving decision-making for cytoreductive nephrectomy by evaluating pre-surgical radiographic tumor characteristics

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, February 2022

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

European Urology, March 2022

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)

ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

The LANCET Oncology, October 2021

Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

PreviousNext